The company has developed a new radio-labeled imaging agent by linking an Indium-based isotope with its proprietary HAAH antibody PAN-622 which has been very successful when tried on animal models with exceptional results and with a radio-labeling yield of 95%. With this new imaging agent, a single body scan can identify the location and size of any cancerous growth anywhere in the body regardless of the type of cancer and at an early stage. Panacea’s imaging agent can be used to visualize tumors in various organs, pinpoint location and size, monitor patients over time, and monitor treatment effects. The all-human antibody allows for repeat imaging and has a rapid and strong binding. It also clears rapidly and offers high contrast and high resolution.
Panacea’s radio imaging agent is currently in preclinical trials. The Phase 1 clinical trials are expected to begin in 2017.